| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
ASK1/JNK pathway (activates apoptosis and autophagy in lung cancer cells); HMGB1/TLR4/NF-κB pathway (anti-inflammatory/anti-fibrotic); COX-2 and MMP-9 (inhibits expression).
|
|---|---|
| ln Vitro |
In vitro, Ecliptasaponin A exerts anti-tumor activity by activating the ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. It exerts anti-inflammatory and anti-fibrotic effects by inhibiting the HMGB1/TLR4/NF-κB pathway and suppressing COX-2 and MMP-9 expression. It also exhibits antioxidant activity, protecting cells from oxidative stress.
|
| ln Vivo |
In vivo, Ecliptasaponin A has protective effects against bleomycin-induced pulmonary fibrosis by reducing oxidative stress, lung tissue inflammation, and subsequent epithelial-mesenchymal transition. It shows hepatoprotective effects, protecting liver cells from damage. It also protects the cardiovascular system. Detailed dose-response data is limited.
|
| Enzyme Assay |
No specific cell-free enzyme/receptor binding assay protocol is detailed for Ecliptasaponin A. For saponin compounds, typical cell-free assays include enzyme inhibition assays (e.g., COX-2, MMP-9 activity assays) using purified enzymes and chromogenic or fluorogenic substrates, or receptor binding assays using radioligands.
|
| Cell Assay |
Cellular activity is assessed in various cell lines (e.g., lung cancer cells for apoptosis/autophagy studies, macrophages for anti-inflammatory studies). Cells are treated with serial dilutions of Ecliptasaponin A. Endpoints include apoptosis detection (flow cytometry, caspase activity), autophagy markers (LC3-II, p62 by Western blot), inflammatory cytokine measurement (ELISA), and cell viability (MTT assay).
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of disease (e.g., bleomycin-induced pulmonary fibrosis in mice). Ecliptasaponin A is administered via oral gavage or intraperitoneal injection. Endpoints include histopathological examination of lung tissue, oxidative stress markers, inflammatory cytokine levels, and fibrosis markers (e.g., collagen deposition).
|
| ADME/Pharmacokinetics |
Molecular weight: 634.84; molecular formula: C36H58O9. Purity: typically ≥98% for research use. Storage: typical for saponin compounds (desiccated, protected from light, -20°C).
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural saponin from a traditional medicinal herb, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development.
|
| References |
|
| Additional Infomation |
Echinocystic acid 3-glucoside is a triterpenoid saponin. It has been reported that wedelia saponin A has been found in both Wedelia chinensis and Wedelia simonii, and related data have been reported.
Ecliptasaponin A is a research-grade compound, not approved for therapeutic use. It is primarily used for pharmacological research in inflammation, cancer, fibrosis, and hepatoprotection. No clinical trials have been reported. Its mechanisms involve ASK1/JNK pathway activation and HMGB1/TLR4/NF-κB pathway inhibition. |
| Molecular Formula |
C36H58O9
|
|---|---|
| Molecular Weight |
634.8403
|
| Exact Mass |
634.408
|
| CAS # |
78285-90-2
|
| PubChem CID |
476537
|
| Appearance |
White to off-white solid powder
|
| Density |
1.27±0.1 g/cm3
|
| Boiling Point |
752.6±60.0 °C at 760 mmHg
|
| Melting Point |
237～238℃
|
| Flash Point |
228.6±26.4 °C
|
| Vapour Pressure |
0.0±5.7 mmHg at 25°C
|
| Index of Refraction |
1.595
|
| LogP |
5.61
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
45
|
| Complexity |
1210
|
| Defined Atom Stereocenter Count |
14
|
| SMILES |
C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(C[C@H]([C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)O)C)C)(C)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O
|
| InChi Key |
WYDPEADEZMZKNM-ZBKPBKBGSA-N
|
| InChi Code |
InChI=1S/C36H58O9/c1-31(2)14-15-36(30(42)43)20(16-31)19-8-9-23-33(5)12-11-25(45-29-28(41)27(40)26(39)21(18-37)44-29)32(3,4)22(33)10-13-34(23,6)35(19,7)17-24(36)38/h8,20-29,37-41H,9-18H2,1-7H3,(H,42,43)/t20-,21+,22-,23+,24+,25-,26+,27-,28+,29-,33-,34+,35+,36+/m0/s1
|
| Chemical Name |
(4aR,5R,6aR,6aS,6bR,8aR,10S,12aR,14bS)-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-10-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~157.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.94 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5752 mL | 7.8760 mL | 15.7520 mL | |
| 5 mM | 0.3150 mL | 1.5752 mL | 3.1504 mL | |
| 10 mM | 0.1575 mL | 0.7876 mL | 1.5752 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
